cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Genmab A S
7 own
4 watching
Current Price
$0
$0.01
(0.03%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
4,061.79M
52-Week High
52-Week High
47.5
52-Week Low
52-Week Low
26.19
Average Volume
Average Volume
0.02M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
13.3069
iconMarket Capitalization4,061.79M
icon52-Week High47.5
icon52-Week Low26.19
iconAverage Volume0.02M
iconDividend Yield--
iconP/E Ratio13.3069
What does the Genmab A S do?
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; a research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Read More
News & Events about Genmab A S.
Globe Newswire
20days ago
Company Announcement COPENHAGEN, Denmark; January 19, 2023 Genmab A/S (Nasdaq: GMAB) Correction: In company announcement no. 1/2023regarding transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons it was reported thatmember of ...
Globe Newswire
1month ago
Company Announcement COPENHAGEN, Denmark; January 3, 2023 Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial...
Globe Newswire
1month ago
Media ReleaseCOPENHAGEN, Denmark; January 2, 2023Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 41stAnnual J.P. Morgan Healthcare Conference in San Francisco at 9:00 AM PST / 12:00 PM EST / 6:00 PM CET on January 11, 2023.The ...
Globe Newswire
1month ago
Media Release COPENHAGEN, Denmark; December 21, 2022 JNDA submission supported by results of Japanese and global phase 2 clinical trials evaluating epcoritamab in patients with mature B-cell non-Hodgkins lymphoma (NHL), including relapsed/refractory large B-cell lymphoma (LBCL) Genmab A/S (Nasdaq: ...
Business Wire
1month ago
Genmab A/S (Nasdaq: GMAB): JNDA submission supported by results of Japanese and global phase 2 clinical trials evaluating epcoritamab in patients with mature B-cell non-Hodgkins lymphoma (NHL), including relapsed/refractory large B-cell lymphoma (LBCL) Genmab A/S (Nasdaq: GMAB) today announced that...
Frequently Asked Questions
Frequently Asked Questions
What is Genmab A S share price today?
plus_minus_icon
Can Indians buy Genmab A S shares?
plus_minus_icon
How can I buy Genmab A S shares from India?
plus_minus_icon
Can Fractional shares of Genmab A S be purchased?
plus_minus_icon
What are the documents required to start investing in Genmab A S stocks?
plus_minus_icon
What is today’s traded volume of Genmab A S?
plus_minus_icon
What is today’s market capitalisation of Genmab A S?
plus_minus_icon
What is the 52-Week High and Low Range of Genmab A S?
plus_minus_icon
What percentage is Genmab A S down from its 52-Week High?
plus_minus_icon
What percentage is Genmab A S up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.01
(0.03%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00